LORLATINIB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 58 adverse event reports in the FDA FAERS database where LORLATINIB was used for Neoplasm malignant.
Most Reported Side Effects for LORLATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 1,050 | 19.1% | 1,047 | 74 |
| Neoplasm progression | 633 | 11.5% | 278 | 155 |
| Off label use | 394 | 7.2% | 97 | 87 |
| Weight increased | 306 | 5.6% | 17 | 46 |
| Hallucination | 290 | 5.3% | 21 | 56 |
| Blood cholesterol increased | 281 | 5.1% | 32 | 47 |
| Dyspnoea | 223 | 4.1% | 49 | 113 |
| Oedema peripheral | 198 | 3.6% | 29 | 62 |
| Oedema | 195 | 3.5% | 17 | 36 |
| Fatigue | 188 | 3.4% | 44 | 49 |
| Peripheral swelling | 164 | 3.0% | 21 | 30 |
| Cognitive disorder | 158 | 2.9% | 11 | 31 |
| Hypercholesterolaemia | 157 | 2.9% | 19 | 43 |
| Blood triglycerides increased | 145 | 2.6% | 19 | 35 |
| Neuropathy peripheral | 142 | 2.6% | 3 | 17 |
Other Indications for LORLATINIB
Non-small cell lung cancer (968)
Lung neoplasm malignant (810)
Non-small cell lung cancer metastatic (285)
Lung adenocarcinoma (269)
Lung cancer metastatic (161)
Neuroblastoma (91)
Product used for unknown indication (88)
Non-small cell lung cancer stage iv (73)
Lung carcinoma cell type unspecified stage iv (54)
Lung carcinoma cell type unspecified stage 0 (51)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)